To develop evidence-based clinical algorithms for community acquired-acute respiratory tract infections CA-ARTI and assess the diagnostic accuracy and the clinical utility of point-of-care tests (POCT) for specific groups of patients, clinical findings, and settings
To develop evidence-based URS’s to support future development and implementation of rapid diagnostics to reduce antimicrobial resistance (AMR) for CA-ARTI, and to refine the methods and processes to make them applicable to POC diagnostic developments for other infectious disease indications
To create a technical roadmap that incorporates recommendations for short- and long-term goals to help companies and research institutions prioritize investment decisions in the field of CA-ARTI diagnostics.
https://value-dx.eu/wp-content/uploads/2019/08/ESCMID-Web.png300300Daniele Pazzolahttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2020-11-26 11:49:102020-11-26 11:52:35ESCMID Policy Statement: addressing the lack of availability of existing antibiotics
https://value-dx.eu/wp-content/uploads/2020/11/ispo.png7201280Tina Hoflandhttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngTina Hofland2020-11-17 14:29:442020-11-18 08:33:48VALUE-Dx at Virtual ISPOR Europe 2020
https://value-dx.eu/wp-content/uploads/2019/09/VALUE-Dx_logo_white4.png4281226Daniele Pazzolahttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2020-09-01 12:27:162020-11-18 08:34:25Webinar with the Expert Advisory Panel on September 30